Cover Image
市場調查報告書

進行性上眼神經核麻痺症:開發中產品分析 (2015年下半年)

Progressive Supranuclear Palsy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 276011
出版日期 內容資訊 英文 77 Pages
訂單完成後即時交付
價格
Back to Top
進行性上眼神經核麻痺症:開發中產品分析 (2015年下半年) Progressive Supranuclear Palsy - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 77 Pages
簡介

由於 進行性上眼神經核麻痺症(PSP)是別名Steele-Richardson-Olszewski症候群的神經退化的難治之症,會出現平衡感覺、移動、視野、會話、吞嚥等沉重的障礙。主要的症狀,有倦怠感和頭痛、暈眩、憂鬱症、帕金森氏症,及行動、認識、步行障礙等,很快導致失衡和關節疼痛。到目前為止證明的風險要素只有年齡。主要的治療方法有抗膽鹼劑的藥物治療等。

提供著對本報告提供進行性上眼神經核麻痺症(PSP)的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等。

目錄

簡介

  • 分析範圍

進行性上眼神經核麻痺症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • AB Science
  • AlzProtect SAS
  • Bristol-Myers Squibb Company
  • Prana Biotechnology Limited
  • ProteoTech, Inc.
  • Sellas Inc.
  • TauRx Therapeutics Ltd.

治療藥的評估

  • 單獨療法的情況
  • 各標靶
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ASN-561
    • 產品概要
    • 作用機制 (MoA)
    • 研究開發 (R&D) 的發展情形
  • AZP-2006
  • BMS-986168
  • DC-TAB
  • DP-C016
  • mashichinibu
  • PBT-434
  • PTI-51CH3
  • PTI-51CH3 Backup
  • TPI-287
  • TRx-0237
  • 酒石酸zorupidemu

開發中產品的最新趨勢

暫停中的企劃

產品開發的里程碑

  • 最新消息和新聞稿 (共2件)

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8855IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2016, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Progressive Supranuclear Palsy Overview
  • Therapeutics Development
    • Pipeline Products for Progressive Supranuclear Palsy - Overview
    • Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis
  • Progressive Supranuclear Palsy - Therapeutics under Development by Companies
  • Progressive Supranuclear Palsy - Therapeutics under Investigation by Universities/Institutes
  • Progressive Supranuclear Palsy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Progressive Supranuclear Palsy - Products under Development by Companies
  • Progressive Supranuclear Palsy - Products under Investigation by Universities/Institutes
  • Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc
    • AlzProtect SAS
    • Asceneuron SA
    • Bristol-Myers Squibb Company
    • Cortice Biosciences Inc
    • Intellect Neurosciences Inc
    • Prana Biotechnology Ltd
    • Sellas Inc
    • TauRx Therapeutics Ltd
  • Progressive Supranuclear Palsy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABBV-8E12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-561 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZP-2006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986168 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DC-TAB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8719 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PBT-434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TauC-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tolfenamic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPI-287 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRx-0237 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zolpidem tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Progressive Supranuclear Palsy - Dormant Projects
  • Progressive Supranuclear Palsy - Product Development Milestones
    • Featured News & Press Releases
      • Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy
      • Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
      • Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases
      • Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Progressive Supranuclear Palsy, H2 2016
  • Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by AB Science SA, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by Intellect Neurosciences Inc, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Ltd, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by Sellas Inc, H2 2016
  • Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Progressive Supranuclear Palsy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Progressive Supranuclear Palsy, H2 2016
  • Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top